Catalent will spend more than $700m to expand development and production capacity for biopharmaceutical products. The CDMO outlined the plan during its Q2 earning call this week, explaining it will spend 15 to 16% of its net revenue in fiscal 2022 – which it expects to be in the $4.74 billion to $4.86 billion range – to expand its biologics business. CFO Thomas Castellano told analysts “We expect CapEx to be approximately 15% to 16% of our fiscal 2022 net…
Through the acquisition of Portuguese CDMO GenIbet Recipharm will move into the biologics drug substance manufacturing space for the first time. Â The Swedish contract development manufacturing organization (CDMO) has traditionally been in the small molecule and fill-finish space, as well as expanding its biologics drug product offering in February 2021 by extending its manufacturing license to include immunology products at its facility in Wasserburg, Germany. Now, Recipharm steps into biologics drug substance manufacturing through the acquisition of Genlbet, a…
The US FDA has revised the emergency use authorizations for Regeneron and Eli Lilly’s COVID-19 antibody treatments after the drugs proved ineffective against the omicron variant. Eli Lilly’s monoclonal antibody (mAb) treatments – bamlanivimab and etesevimab (administered together) and Regeneron’s REGEN-COV (casirivimab and imdevimab) will be limited to use only “if patients in certain geographic regions are likely to be infected or exposed to a variant that is susceptible to these treatments,†the US Food and Drug Administration (FDA) said…